Symptomatic treatment of chronic obstructive pulmonary disease (COPD) by next-generation bronchodilators has improved considerably over the past decade: Long-acting beta-agonists and long-acting muscarinic antagonists (also as combined fixed-dose inhalation) are now available for long-term maintenance. However, there has been very little progress in developing anti-inflammatory drugs that specifically target inflammation in COPD [1]. More than 10 years ago, several inflammatory pathways and potential drugs in early-phase development for COPD were summarised in two well-known review articles [2, 3]. However, of the drug candidates listed there, only the oral phosphodiesterase-4 inhibitor roflumilast made it to regulatory approval; its anti-inflammatory effects resulted in a reduction of exacerbations and modest improvements in lung function [1, 4]. Other drugs either failed to show a clear benefit, or drug development was stopped because of safety concerns [5]. This has made the past decade disappointing for the development of novel anti-inflammatory therapies in COPD [1]. The MAPK inhibitor RV568 might be the next generation of anti-inflammatory therapy for COPD http://ow.ly/vccD30fNP3c

中文翻译：

---

COPD的下一代抗炎疗法？

在过去十年中，下一代支气管扩张剂对慢性阻塞性肺疾病 (COPD) 的对症治疗有了显着改善：长效 β-激动剂和长效毒蕈碱拮抗剂（也作为联合固定剂量吸入）现在可用于长期期限维护。然而，在开发专门针对 COPD 炎症的抗炎药物方面进展甚微[1]。10 多年前，两篇著名的综述文章总结了 COPD 早期发展中的几种炎症途径和潜在药物 [2, 3]。然而，在那里列出的候选药物中，只有口服磷酸二酯酶 4 抑制剂罗氟司特获得了监管部门的批准；其抗炎作用导致急性加重的减少和肺功能的适度改善 [1, 4]。其他药物要么没有显示出明显的益处，要么由于安全问题而停止了药物开发[5]。这使得过去十年中 COPD 新型抗炎疗法的开发令人失望 [1]。MAPK 抑制剂 RV568 可能是 COPD 的下一代抗炎疗法 http://ow.ly/vccD30fNP3c